Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
Alaunos Therapeutics reported integrated preclinical data for ALN1003, showing broad metabolic improvements in diet-induced obese mice, including up to 30.5% body weight loss and 43% liver weight reduction. The data comes from two non-GLP mouse studies. The CEO cautioned that these are early findings that must be interpreted with care and do not guarantee human efficacy.
Key figures
- Drug Name
- ALN1003
- Cash runway
- Q2 2026
- Cash and equivalents
- 354000
- Body weight reduction study1
- -10.3%
- Liver weight reduction study1
- -43%
- Fat mass reduction study2 high dose
- -44.6%
- Body weight reduction study2 high dose
- -30.5%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.